UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan

Abstract Background Sacituzumab govitecan (sacituzumab) emerged as an important agent in metastatic and locally recurrent HER2‐negative breast cancer treatment. UGT1A1 polymorphisms have also been shown to predict sacituzumab toxicity. Methods In this retrospective study, we sought to evaluate the a...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	Megan H. Wong, Veronica C. Jones, Wai Yu, Linda D. Bosserman, Sayeh M. Lavasani, Niki Patel, Mina S. Sedrak, Daphne B. Stewart, James R. Waisman, Yuan Yuan, Joanne E. Mortimer
Format:	Article
Language:	English
Published:	Wiley 2024-08-01
Subjects:	metastatic breast cancer pharmacogenetics sacituzumab govitecan SN‐38 toxicity UGT1A1*28
Online Access:	https://doi.org/10.1002/cam4.70096